Acidosis

SIBIONICS Launches the Breakthrough SIBIO KS1 CKM for Ketone Level Monitoring

Retrieved on: 
Tuesday, September 5, 2023

SHENZHEN, China, Sept. 5, 2023 /PRNewswire/ -- SIBIONICS, a leader in bio-wearable consumer electronics, is pleased to announce the launch of SIBIO KS1 Continuous Ketone Monitoring (CKM) System, the company's newest biometric wearable device designed to measure ketone levels.

Key Points: 
  • SHENZHEN, China, Sept. 5, 2023 /PRNewswire/ -- SIBIONICS, a leader in bio-wearable consumer electronics, is pleased to announce the launch of SIBIO KS1 Continuous Ketone Monitoring (CKM) System, the company's newest biometric wearable device designed to measure ketone levels.
  • Boasting CE certification for wearable biosensors for monitoring healthcare, the KS1 is the world's first all-in-one sensor and transmitter that provides real-time monitoring for ketone diet practitioners.
  • "The purpose for developing the SIBIO KS1 CKM was to expand the previous biometric sensing technology SIBIONICS has already mastered to provide higher quality and more precise monitoring capabilities.
  • SIBIONICS has announced the free trial availability of the SIBIO KS1 CKM.

SIBIONICS Launches the Breakthrough SIBIO KS1 CKM for Ketone Level Monitoring

Retrieved on: 
Tuesday, September 5, 2023

SHENZHEN, China, Sept. 5, 2023 /PRNewswire/ -- SIBIONICS, a leader in bio-wearable consumer electronics, is pleased to announce the launch of SIBIO KS1 Continuous Ketone Monitoring (CKM) System, the company's newest biometric wearable device designed to measure ketone levels.

Key Points: 
  • SHENZHEN, China, Sept. 5, 2023 /PRNewswire/ -- SIBIONICS, a leader in bio-wearable consumer electronics, is pleased to announce the launch of SIBIO KS1 Continuous Ketone Monitoring (CKM) System, the company's newest biometric wearable device designed to measure ketone levels.
  • Boasting CE certification for wearable biosensors for monitoring healthcare, the KS1 is the world's first all-in-one sensor and transmitter that provides real-time monitoring for ketone diet practitioners.
  • "The purpose for developing the SIBIO KS1 CKM was to expand the previous biometric sensing technology SIBIONICS has already mastered to provide higher quality and more precise monitoring capabilities.
  • SIBIONICS has announced the free trial availability of the SIBIO KS1 CKM.

After Record Growth in 2022, Etiometry Paves Way for 2023 Expansion

Retrieved on: 
Tuesday, January 31, 2023

On the heels of record growth in 2021, Etiometry harnessed the momentum moving into 2022, more than doubling sales over 2021, and also initiated its first adult hospital installations.

Key Points: 
  • On the heels of record growth in 2021, Etiometry harnessed the momentum moving into 2022, more than doubling sales over 2021, and also initiated its first adult hospital installations.
  • On the regulatory front, Etiometry announced this month its eighth FDA clearance ; the IDO2 IndexTM is now cleared for adult use.
  • “Our regulatory success uniquely positions Etiometry for further developments in 2023 that will result in enhanced offerings benefiting patients and the care teams treating them,” said Shane Cooke, CEO of Etiometry.
  • Capping off the year, Frost & Sullivan presented Etiometry with its Enabling Technology Leadership Award for critical care decision making.

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

Retrieved on: 
Saturday, June 4, 2022

This Phase 1, mechanistic study evaluated the effects of the GKA TTP399 on ketoacidosis risk in individuals with T1D on insulin pump therapy.

Key Points: 
  • This Phase 1, mechanistic study evaluated the effects of the GKA TTP399 on ketoacidosis risk in individuals with T1D on insulin pump therapy.
  • No subject treated with TTP399 met the prespecified definition of DKA while 42% of placebo-treated subjects met this criterion.
  • Together, these data suggest that TTP399 does not increase, and may decrease, the risk of diabetic ketoacidosis (DKA) in subjects with T1D.
  • This past October, vTv announced results of a mechanistic study of TTP399 in patients with type 1 diabetes demonstrating no increased risk of ketoacidosis.

Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug SibnayalTM in dRTA

Retrieved on: 
Monday, December 20, 2021

Distal renal tubular acidosis (dTRA) is an orphan disease characterized by the inability of the kidney to excrete acids from metabolism.

Key Points: 
  • Distal renal tubular acidosis (dTRA) is an orphan disease characterized by the inability of the kidney to excrete acids from metabolism.
  • Advicenne (Euronext: ADVIC) is a pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology.
  • Its lead drug candidate is currently in late-stage clinical trials for two kidney diseases: distal renal tubular acidosis and cystinuria.
  • ADV7103 has just received a positive CHMP opinion for the treatment of dRTA.

Marler Clark Files Lawsuits in Nationwide Salmonella Onion Outbreak

Retrieved on: 
Tuesday, December 7, 2021

BOISE, Idaho, Dec. 7, 2021 /PRNewswire/ --Three lawsuits have been filed against Prosource Produce, LLC, on behalf of victims of a nationwide Salmonella outbreak linked to onions which to date has sickened nearly 900 people.

Key Points: 
  • BOISE, Idaho, Dec. 7, 2021 /PRNewswire/ --Three lawsuits have been filed against Prosource Produce, LLC, on behalf of victims of a nationwide Salmonella outbreak linked to onions which to date has sickened nearly 900 people.
  • "This Salmonella Oranienburgoutbreak has hospitalized more than most outbreaks of similar size," said William D. Marler, managing partner at Marler Clark.
  • "In addition, this is the second significant Salmonella outbreak linked to onions in the past two years," added Marler.
  • As of November 12, 2021, 892 people infected with the outbreak strain of Salmonella Oranienburg have been reported from 38 states and Puerto Rico.

Cyteir Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

Retrieved on: 
Friday, November 12, 2021

Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the third quarter ended September 30, 2021 and provided an update on recent business highlights.

Key Points: 
  • Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the third quarter ended September 30, 2021 and provided an update on recent business highlights.
  • With the dose escalation portion of the study complete, the Phase 2 dose has been identified as 400 mg per day.
  • Simultaneously, we are initiating Phase 2 expansion study into disease-specific cohorts and expect to begin enrolling patients in the first quarter of 2022.
  • Cash and cash equivalents: Cash and cash equivalents for the quarter ended September 30, 2021, were $199.8 million.

Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 9, 2021

Retrieved on: 
Wednesday, July 28, 2021

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis and slow CKD progression in patients with CKD.

Key Points: 
  • Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis and slow CKD progression in patients with CKD.
  • Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration.
  • There are no FDA-approved treatments for chronic metabolic acidosis.
  • It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

Shareholder Alert: Robbins LLP is Investigating Tricida, Inc. (TCDA) for Shareholders

Retrieved on: 
Friday, June 4, 2021

Shareholder rights law firm Robbins LLP is investigating Tricida, Inc. (NASDAQ: TCDA) to determine whether certain Tricida officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company.

Key Points: 
  • Shareholder rights law firm Robbins LLP is investigating Tricida, Inc. (NASDAQ: TCDA) to determine whether certain Tricida officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company.
  • Its lead drug candidate veverimer (TRC101) is intended to slow the progression of chronic kidney disease ("CKD") through the treatment of metabolic acidosis.
  • If you would like more information regarding your rights, please contact Lauren Levi at (800) 350-6003 or [email protected] , or via our Shareholder Information Form .
  • Robbins LLP is a nationally recognized leader in shareholder rights law.

Tricida to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

Retrieved on: 
Wednesday, June 2, 2021

(Nasdaq: TCDA) today announced that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 12:50 pm PT / 3:50 pm ET.

Key Points: 
  • (Nasdaq: TCDA) today announced that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 12:50 pm PT / 3:50 pm ET.
  • Gerrit Klaerner, Tricidas Founder, President and Chief Executive Officer, will provide a company overview, business update and progress on the companys key initiatives.
  • A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com .
  • Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD.